MEDICAL DEVELOPMENTS INTL

Medical Developments International reported a 9% increase in group revenue for fiscal 2026 to 42.6 million AUD, driven by pain management with Penthrox (revenue +21% to 31 million AUD). The respiratory products segment saw a 15% revenue decline. Free cash flow improved to 4.2 million AUD and the cash balance rose to 21.4 million AUD; the company made no comment on EPS forecasts. The stock reacted with a decline of about 1.94%. Management called the pediatric approval in Europe a milestone and expects higher demand, plans investments in production and targeted market expansions, but sees risks from weak demand in respiratory products, exchange rates and tariff uncertainties. » More on de.investing.com

For fiscal 2026 Medical Developments International reported group revenue of AUD 42.6m (+9%), driven by a 21% increase in pain management to AUD 31m due to demand for Penthrox in Australia and Europe. The respiratory segment saw a 15% decline in sales, while free cash flow and cash holdings rose to AUD 4.2m and AUD 21.4m, respectively. Management called the paediatric approval of Penthrox in Europe a strategic milestone and expects further growth for Penthrox in fiscal 2027, but sees weaker prospects in the respiratory area. The stock lost 1.94% and remains below its 52‑week high; analysts cited in the report see substantial upside potential. » More on de.investing.com